Ian M. Waxman
- Oncology top 1%
- Cancer Immunotherapy and Biomarkers 20
- CAR-T cell therapy research 11
- Pancreatic and Hepatic Oncology Research 3
- Immunology top 5%
-
- Renal cell carcinoma treatment 12
- Cancer Research top 10%
- Cancer Genomics and Diagnostics 4
- Genetics top 5%
-
- Lymphoma Diagnosis and Treatment 7
-
- Melanoma and MAPK Pathways 5
-
- Acute Lymphoblastic Leukemia research 3
- Co-authors
- Robert J. MotzerElizabeth R. PlimackCaroline RobertHans J. HammersSaby GeorgeJoel JiangMario SznolSuzanne L. Topalian
- Partner nations
- United StatesFranceGermany
In The Last Decade
Ian M. Waxman
34 papers receiving 2.7k citations
Hit Papers
Peers
Comparison fields: 5 of 85
- Oncology 2.3k
- Immunology 717
- Pulmonary and Respiratory Medicine 993
- Cancer Research 294
- Genetics 186
Countries citing papers authored by Ian M. Waxman
This map shows the geographic impact of Ian M. Waxman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian M. Waxman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian M. Waxman more than expected).
Fields of papers citing papers by Ian M. Waxman
This network shows the impact of papers produced by Ian M. Waxman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian M. Waxman. The network helps show where Ian M. Waxman may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Ian M. Waxman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 1 | |
| 2 | 2022 | 5 | |
| 3 | 2017 | 142 | |
| 4 | 2016 | 3 | |
| 5 | 2016 | 89 | |
| 6 | 2016 | 57 | |
| 7 | 2016 | 12 | |
| 8 | 2016 | 33 | |
| 9 | 2016 | 27 | |
| 10 | 2015 | 1 | |
| 11 | 2015 | 3 | |
| 12 | 2015 | 11 | |
| 13 | Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trialbreakdown → | 2014 | 865 |
| 14 | 2014 | 55 | |
| 15 | 2011 | 1 | |
| 16 | 2010 | 29 | |
| 17 | 2008 | 68 | |
| 18 | 2008 | 18 | |
| 19 | 2008 | 0 | |
| 20 | 2007 | 1 |
About Ian M. Waxman
Ian M. Waxman is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine, having authored 35 papers that have together received 2.8k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (20 papers), Renal cell carcinoma treatment (12 papers), CAR-T cell therapy research (11 papers), Lymphoma Diagnosis and Treatment (7 papers), Melanoma and MAPK Pathways (5 papers), Cancer Genomics and Diagnostics (4 papers), Pancreatic and Hepatic Oncology Research (3 papers) and Acute Lymphoblastic Leukemia research (3 papers). The work is most often cited by research in Oncology (2.3k citations), Immunology (717 citations) and Pulmonary and Respiratory Medicine (993 citations). Ian M. Waxman has collaborated with scholars based in United States, France and Germany. Frequent co-authors include Robert J. Motzer, Elizabeth R. Plimack, Caroline Robert, Hans J. Hammers, Saby George, Joel Jiang, Mario Sznol, Suzanne L. Topalian, Dirk Schadendorf and Jeffrey S. Weber. Their work appears in journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.